Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07300969 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
A Phase 2 study of Major Depressive Disorder (MDD), sponsored by Draig Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT07300969: Recruiting Phase 2 study of Major Depressive Disorder (MDD), sponsored by Draig Therapeutics.
NCT07300969 is a Phase 2 study of Major Depressive Disorder (MDD) that is actively recruiting participants, run by Draig Therapeutics. The registered enrollment target is 300 participants, above the 145-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (107% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07300969, a Phase 2 study of Major Depressive Disorder (MDD), is actively recruiting participants, sponsored by Draig Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DT-101
Study Locations (20)
California
- Draig Clinical Site - Oceanside
- Draig Clinical Site - San Diego
- Draig Clinical Site - Torrance
Florida
- Draig Clinical Site - Miami
- Draig Clinical Site - New Port Richey
- Draig Clinical Site - Orlando
Texas
- Draig Clinical Site - Austin
- Draig Clinical Site - DeSoto
- Draig Clinical Site - Richardson
Arkansas
- Draig Clinical Site - Bentonville
- Draig Clinical Site - Little Rock
Georgia
- Draig Clinical Site - Atlanta
- Draig Clinical Site - Decatur
Maryland
- Draig Clinical Site - Gaithersburg
Massachusetts
- Draig Clinical Site - Watertown
Mississippi
- Draig Clinical Site - Flowood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
What NCT07300969 shows while recruiting
NCT07300969 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 145-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (107% higher).
The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07300969 names 20 study sites across 12 states, led by California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07300969 about?
NCT07300969 is a clinical study titled "A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression". The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.
What is the current status of trial NCT07300969?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2025-12-16. Estimated completion is 2027-08.
What conditions does trial NCT07300969 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT07300969?
The interventions under investigation include: Placebo (DRUG), DT-101 (DRUG).
Who is sponsoring clinical trial NCT07300969?
This trial is sponsored by Draig Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07300969 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07300969's enrollment target sits among peer trials
300 5th of 22 higher than 18 of 22 other Major Depressive Disorder (MDD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder (MDD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
RECRUITING · Phase 2
-
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
ACTIVE NOT RECRUITING · Phase 2
-
A Study in Patients With Major Depressive Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Improving Depression Outcome by Enhancing Memory for Cognitive Therapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI